MarketCap
Facebook
X
Telegram
Sio Gene Therapies Balance Sheet 2022-2011 | SIOX
Brief balance sheet overview of Sio Gene Therapies
The balance sheet is assessed across five available annual reports spanning 2018 to 2022.
The asset base decreased -53.3%, from $160.8 million to $75.1 million. Resources became smaller over the five periods.
Liabilities increased less than assets, posting -83.5% versus -53.3%. That relationship usually strengthens the balance sheet.
Equity funds 80.4% of assets versus 44.3% initially. This creates a conservative balance sheet structure.
Net debt moved below zero to -$61.2 million, reflecting surplus cash over debt.
Cash equals 84.9% of the balance sheet, compared with 96% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$863 million. It should be assessed alongside historical profits and capital distributions.
What the balance sheet shows
Sio Gene Therapies has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Sio Gene Therapies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-61.2 M | -118 M | -64.4 M | -62.8 M | -102 M | -161 M | -276 M | - | - | - | - | - |
Long Term Debt |
1.73 M | 932 K | 15.4 M | 23 M | 42.9 M | 51.4 M | - | - | - | - | - | - |
Long Term Debt Current |
786 K | 311 K | 889 K | 21.2 M | 9.75 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 15.4 M | 23 M | 42.9 M | 51.4 M | - | 5 M | - | - | - | - |
Total Current Liabilities |
13 M | 10.8 M | 32 M | 43.5 M | 46.6 M | 46.3 M | 15.8 M | 3.87 M | - | - | - | - |
Total Liabilities |
14.7 M | 11.8 M | 32.1 M | 66.5 M | 89.5 M | 97.7 M | 15.8 M | 8.87 M | - | - | - | - |
Retained Earnings |
-863 M | -791 M | -759 M | -686 M | -557 M | -335 M | -154 M | -21 M | - | - | - | - |
Total Assets |
75.1 M | 135 M | 93.7 M | 123 M | 161 M | 223 M | 282 M | 1.12 M | - | - | - | - |
Cash and Cash Equivalents |
63.7 M | 119 M | 80.8 M | 107 M | 154 M | 213 M | 276 M | - | - | - | - | - |
Book Value |
60.3 M | 123 M | 61.6 M | 56.2 M | 71.3 M | 125 M | 267 M | -7.75 M | - | - | - | - |
Total Shareholders Equity |
60.3 M | 123 M | 61.6 M | 56.2 M | 71.3 M | 125 M | 267 M | -7.75 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Sio Gene Therapies
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 1.55 M | - | 1.9 M | 865 K | 921 K | 1.9 M | 986 K | 55 K | 71 K | 986 K | 6.45 M | 71 K | 17.5 M | 6.45 M | 28.3 M | 11.7 M | 38.2 M | 28.3 M | 47.6 M | 52.1 M | 51.8 M | 47.6 M | 52.1 M | 51.8 M | 51.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.15 M | 4.83 M | 10.7 M | 2.15 M | 17 M | 11.2 M | 8.52 M | 17 M | 9.94 M | 10.1 M | 12.5 M | 9.94 M | 37.2 M | 12.5 M | 72.1 M | 37.2 M | 73.5 M | 59 M | 81.8 M | 73.5 M | 89.7 M | 93 M | 103 M | 89.7 M | 39.6 M | 28.6 M | 16.9 M | 39.6 M | 15.9 M | 10.4 M | 9.57 M | 15.9 M | 10.4 M | 9.57 M | 8.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-878 M | -874 M | -871 M | -878 M | -850 M | -824 M | -803 M | -850 M | -788 M | -777 M | -767 M | -788 M | -742 M | -767 M | -714 M | -742 M | -677 M | -728 M | -609 M | -677 M | -532 M | -474 M | -405 M | -532 M | -282 M | -234 M | -192 M | -282 M | -125 M | -61.2 M | -49.1 M | -125 M | -61.2 M | -49.1 M | -21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
47.3 M | 53.7 M | 62.5 M | 47.3 M | 93.3 M | 111 M | 122 M | 93.3 M | 99 M | 79.8 M | 71 M | 99 M | 42.3 M | 71 M | 101 M | 42.3 M | 96.2 M | 76.1 M | 108 M | 96.2 M | 196 M | 246 M | 309 M | 196 M | 206 M | 235 M | 257 M | 206 M | 304 M | 323 M | 331 M | 304 M | 323 M | 331 M | 1.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
46.1 M | 49.9 M | 54.8 M | 46.1 M | 81.9 M | 102 M | 111 M | 81.9 M | 81 M | 63.2 M | 55.5 M | 81 M | 27.8 M | 63.2 M | 84.2 M | 27.8 M | 84.9 M | 60.3 M | 92.9 M | 84.9 M | 188 M | 235 M | 298 M | 188 M | 200 M | 230 M | 253 M | 200 M | 300 M | 320 M | 331 M | 300 M | 320 M | 331 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
45.1 M | 48.9 M | 51.8 M | 45.1 M | 76.3 M | 99.4 M | 113 M | 76.3 M | 89 M | 69.7 M | 58.6 M | 89 M | 5.05 M | 58.6 M | 29.4 M | 5.05 M | 22.8 M | 17 M | 25.8 M | 22.8 M | 107 M | 153 M | 206 M | 107 M | 166 M | 206 M | 240 M | 166 M | 288 M | 312 M | 322 M | 288 M | 312 M | 322 M | -7.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
45.1 M | 48.9 M | 51.8 M | 45.1 M | 76.3 M | 99.4 M | 113 M | 76.3 M | 89 M | 69.7 M | 58.6 M | 89 M | 5.05 M | 69.7 M | 29.4 M | 5.05 M | 22.8 M | 17 M | 25.8 M | 22.8 M | 107 M | 153 M | 206 M | 107 M | 166 M | 206 M | 240 M | 166 M | 288 M | 312 M | 322 M | 288 M | 312 M | 322 M | -7.75 M | -5.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Sio Gene Therapies, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.